カテゴリ： Global Markets Direct, 医療/バイオ

麻酔効果治療薬市場：パイプラインレビュー（2020年上半期）

◆英語タイトル：Anesthetic Effect - Pipeline Review, H1 2020
◆商品コード：GDATA20MY0920
◆発行会社（リサーチ会社）：Global Markets Direct
◆発行日：2020年3月31日
◆ページ数：97
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,000 ⇒換算￥220,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD4,000 ⇒換算￥440,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD6,000 ⇒換算￥660,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

Anesthetic Effect – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect – Pipeline Review, H1 2020, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 1, 4, 1, 12, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anesthetic Effect – Overview
Anesthetic Effect – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anesthetic Effect – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anesthetic Effect – Companies Involved in Therapeutics Development
Andros Pharmaceuticals Co Ltd
Avecho Biotechnology Ltd
Baudax Bio Inc
Biotts SA
Crescita Therapeutics Inc
Cuda Pharmaceuticals LLC
Drawbridge Pharmaceuticals Pty Ltd
Expanesthetics Inc
Hangzhou Adamerck Pharmlabs Inc
Hefei Cosource Pharmaceutical Inc
Jiangsu Hengrui Medicine Co Ltd
Lannett Co Inc
Lee’s Pharmaceutical Holdings Ltd
LipoSeuticals Inc
MedinCell SA
NutriBand Inc
Paion AG
Physica Pharma
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sphaera Pharma Pte Ltd
Yichang Humanwell Pharmaceutical Co Ltd
Anesthetic Effect – Drug Profiles
(lidocaine + tetracaine) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alphaxalone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aom-0498 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aom-0765 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APC-310 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cocaine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclopentol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cysteine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-05 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-09 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fospropofol disodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HR-7056 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HYRPB-21 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-100137 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
morphine glucuronide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTCA-4 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHY-301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam besylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropivacaine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-1000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-2000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block NaV1.7 for Local Anesthetic Effect – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NMDA Receptor for Anaesthesia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-819 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anesthetic Effect – Dormant Projects
Anesthetic Effect – Discontinued Products
Anesthetic Effect – Product Development Milestones
Featured News & Press Releases
Mar 12, 2020: Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO
Jan 23, 2020: PAION : Mundipharma receives market approval for Anerem (Remimazolam) in general anesthesia in Japan
Jan 13, 2020: Lannett announces FDA approval of NDA for branded anesthetic product, Cocaine Hydrochloride nasal solution 4%
Dec 30, 2019: Paion announces submission of new drug application for remimazolam by its licensee Hana Pharm in South Korea
Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency
Jul 16, 2019: United States Patent and Trademark Office issues U.S. patent covering an enhanced formulation of Pliaglis
Jun 28, 2019: EIB and German specialty pharmaceutical company PAION AG have signed a €20 million loan agreement
Jun 11, 2019: Hana Pharm presented clinical trial results of Remimazolam at International Congress of Cardiothoracic and Vascular Anesthesia
Jun 10, 2019: FDA accepts filing of NDA for Remimazolam
Apr 09, 2019: Cosmo Pharmaceuticals announces submission of Remimazolam NDA to FDA
Nov 06, 2018: R-Pharm Group and Paion announce successful completion of remimazolam phase III clinical trial
Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea
Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia
May 17, 2018: Paion announces clinical development progress with Remimazolam by its partner R-Pharm in Russia
Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anesthetic Effect, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Anesthetic Effect - Pipeline by Andros Pharmaceuticals Co Ltd, H1 2020
Anesthetic Effect - Pipeline by Avecho Biotechnology Ltd, H1 2020
Anesthetic Effect - Pipeline by Baudax Bio Inc, H1 2020
Anesthetic Effect - Pipeline by Biotts SA, H1 2020
Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H1 2020
Anesthetic Effect - Pipeline by Cuda Pharmaceuticals LLC, H1 2020
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2020
Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2020
Anesthetic Effect - Pipeline by Hangzhou Adamerck Pharmlabs Inc, H1 2020
Anesthetic Effect - Pipeline by Hefei Cosource Pharmaceutical Inc, H1 2020
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Anesthetic Effect - Pipeline by Lannett Co Inc, H1 2020
Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
Anesthetic Effect - Pipeline by LipoSeuticals Inc, H1 2020
Anesthetic Effect - Pipeline by MedinCell SA, H1 2020
Anesthetic Effect - Pipeline by NutriBand Inc, H1 2020
Anesthetic Effect - Pipeline by Paion AG, H1 2020
Anesthetic Effect - Pipeline by Physica Pharma, H1 2020
Anesthetic Effect - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H1 2020
Anesthetic Effect - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H1 2020
Anesthetic Effect - Pipeline by SiteOne Therapeutics Inc, H1 2020
Anesthetic Effect - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
Anesthetic Effect - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
Anesthetic Effect - Dormant Projects, H1 2020
Anesthetic Effect - Dormant Projects, H1 2020 (Contd..1), H1 2020
Anesthetic Effect - Discontinued Products, H1 2020

【掲載企業】

Andros Pharmaceuticals Co Ltd
Avecho Biotechnology Ltd
Baudax Bio Inc
Biotts SA
Crescita Therapeutics Inc
Cuda Pharmaceuticals LLC
Drawbridge Pharmaceuticals Pty Ltd
Expanesthetics Inc
Hangzhou Adamerck Pharmlabs Inc
Hefei Cosource Pharmaceutical Inc
Jiangsu Hengrui Medicine Co Ltd
Lannett Co Inc
Lee's Pharmaceutical Holdings Ltd
LipoSeuticals Inc
MedinCell SA
NutriBand Inc
Paion AG
Physica Pharma
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sphaera Pharma Pte Ltd
Yichang Humanwell Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[麻酔効果治療薬市場：パイプラインレビュー（2020年上半期）]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 麻酔効果治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0093 / Global Markets Direct / 2019年11月25日 / ...Anesthetic Effect - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2019, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape. Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central...
  2. 糖尿病性胃不全麻痺治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0808 / Global Markets Direct / 2020年2月28日 / ...Diabetic Gastroparesis - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2020, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are...
  3. 軟骨形成不全症治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0910 / Global Markets Direct / 2020年3月31日 / ...Achondroplasia - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Achondroplasia - Pipeline Review, H1 2020, provides an overview of the Achondroplasia (Musculoskeletal Disorders) pipeline landscape. Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, short arms and legs, disproportionately large head compared to the body and kyphosis. Treatment includes growth hormones. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Achondroplasia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under...
  4. タンパク質含有ブロモドメイン2治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0824 / Global Markets Direct / 2020年2月28日 / ...Bromodomain Containing Protein 2 - Pipeline Review, H1 2020 Summary Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are...
  5. ヒトサイトメガロウイルスエンベロープ糖タンパク質B治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0826 / Global Markets Direct / 2020年2月28日 / ...Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H1 2020 Summary Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Cytomegalovirus Envelope Glycoprotein B- Pipeline Review, H1 2020, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in...
  6. タンパク質含有ブロモドメイン3治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0825 / Global Markets Direct / 2020年2月28日 / ...Bromodomain Containing Protein 3 - Pipeline Review, H1 2020 Summary According to the recently published report 'Bromodomain Containing Protein 3 - Pipeline Review, H1 2020'; Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Bromodomain-containing protein 3 (BRD3) or RING3-like protein (RING3L) is a protein that encodes the BRD3 gene. It plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors....
  7. バッテン病治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0797 / Global Markets Direct / 2020年2月28日 / ...Batten Disease - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H1 2020, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone and movement problems. Report Highlights...
  8. 眼瞼炎治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0873 / Global Markets Direct / 2020年2月28日 / ...Blepharitis - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2020, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape. Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide...
  9. 薬物過剰摂取治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0916 / Global Markets Direct / 2020年3月31日 / ...Drug Overdose - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H1 2020, provides an overview of the Drug Overdose (Toxicology) pipeline landscape. Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest...
  10. 心筋炎治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0790 / Global Markets Direct / 2020年2月28日 / ...Myocarditis - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H1 2020, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape. Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆